Something doesn’t add up when a patient is doing everything right –taking their medications, avoiding known triggers, following up regularly and still ends up in the ER twice a year. Or still needs a round of prednisone every time the seasons change. Or still can’t get through a full night of sleep without waking up tight in the chest.
That’s biology that hasn’t been addressed at the right level yet.
That is precisely what biologic therapy addresses. However, this is not quite as easy because these are targeted drugs that cost a lot of money, and they are used for those who already have certain clinical criteria, and even those criteria are much more complicated than you think.
The Basics: What Makes Biologics Different
You get told what standard asthma treatments will do: Achieve significantly better asthma control – inhaled corticosteroids, long-acting beta-agonists, and leukotriene modifiers act broadly. Three of them diminish overall airway inflammation or dilate narrowed bronchi. For many asthma patients, that is sufficient.
Biologics operate differently. These are laboratory-developed monoclonal antibodies that target proteins and immune pathways shown to mediate asthma present in specific patients. They do not broadly inhibit inflammation but interrupt it at a specific molecular level.
The Food and Drug Administration (FDA) has approved several biologics for asthma: omalizumab (Xolair), mepolizumab (Nucala), benralizumab (Fasenra), dupilumab (Dupixent), and tezepelumab (Tezspire). They all inhibit a part of the inflammatory cascade and therefore, patient selection is never uniform. A biologic that works for one person – based on their biomarker profile – may not be the right choice for another; each immune picture is unique.
Who Gets Evaluated: The Starting Point
Biologic therapy is not a first-line treatment. It is an add-on therapy considered after standard treatment has been properly optimized and still found inadequate.
In clinical practice, the patients who get referred for biologic evaluation generally share a few characteristics:
- Moderate-to-severe persistent asthma.
- Frequent exacerbations.
- Typically two or more in the prior 12 months requiring systemic steroids or an emergency visit and symptoms that persist despite being on medium-to-high dose inhaled corticosteroids, often alongside a long-acting bronchodilator.
Persistent nighttime wakening due to asthma. Significant activity limitation. FEV1 that doesn’t normalize even with treatment. These are the patterns that prompt a specialist to look further.
If standard therapy is working well, biologics aren’t on the table. But if standard therapy has hit a ceiling, if there’s a pattern of ongoing burden despite doing things correctly, that ceiling deserves to be challenged.
Biomarkers: Where Candidacy Gets Specific
This is the part of the conversation that often surprises patients. Qualifying for a biologic isn’t just about how bad your asthma feels. It’s about what’s driving it — specifically, whether your immune system is producing the type of inflammation that a given biologic is designed to interrupt.
Most currently approved biologics target what’s called Type 2, or T2, inflammation. This is an immune response pattern mediated by certain white blood cells and signaling proteins, eosinophils, IgE antibodies, and cytokines, including IL-4, IL-5, and IL-13. Patients with this profile are sometimes called “T2-high,” and they tend to respond well to the biologics that target these pathways.
Not every asthma patient has a T2-high profile. Identifying yours requires specific testing.
Blood eosinophil count is one of the first things checked. Elevated counts, thresholds vary by biologic, but generally above 150 to 300 cells per microliter suggest a patient may respond to IL-5 pathway agents like mepolizumab or benralizumab. A count above 300 strengthens that signal considerably.
Total serum IgE and confirmed allergen sensitization through skin testing or specific IgE blood panels are required for omalizumab candidacy. Omalizumab targets the IgE pathway and is specifically indicated for allergic asthma, so allergy testing isn’t just background information here; it’s part of the eligibility determination.
Fractional exhaled nitric oxide, or FeNO, is a breath test that measures airway eosinophilic inflammation directly. A high FeNO reading supports T2 inflammation and helps guide which biologic direction makes the most clinical sense.
Tezepelumab, the newest approved option, targets thymic stromal lymphopoietin – a protein released by airway epithelial cells that sits upstream of multiple inflammatory pathways. Because it acts before the T2 response even begins, it has shown benefit across a broader range of asthma phenotypes, including some patients who don’t have elevated eosinophils or IgE. This has meaningfully expanded biologic eligibility for patients who previously didn’t meet the classic biomarker criteria.
Oral Corticosteroid Dependence: A Signal That Matters
Patients who have come to rely on oral corticosteroids – prednisone, prednisolone – to keep their asthma from spiraling deserve particular attention in this conversation!
Chronic oral steroid use carries a real cumulative burden like osteoporosis, weight gain, adrenal suppression, elevated blood glucose, increased cardiovascular risk and cataracts. These are not hypothetical concerns – they’re documented outcomes in long-term OCS-dependent patients.
When someone is regularly reaching for systemic steroids just to maintain baseline function, that’s a clinical red flag, not a stable situation.
Reducing or eliminating oral corticosteroid dependence is one of the primary treatment goals in severe asthma management.
Despite variability in agents and definitions of OCS exposure reduction, multiple clinical trials have consistently shown substantial OCS reductions, with around 1/4th of patients able to completely discontinue.
Its presence in your history is a compelling case for considering a biologic evaluation if you have been on chronic steroids. While this does not guarantee the candidacy, it establishes a more stable foundation for conversation.
Comorbidities That Can Strengthen
Severe asthma rarely travels alone. other chronic diseases (such as chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis) – which are all associated with an overlapping inflammatory biology.
In some instances, those comorbidities actually strengthen the case for a biologic treatment. An example of this type of drug is dupilumab, which is FDA-approved for moderate-to-severe asthma, moderate-to-severe atopic dermatitis, and chronic rhinosinusitis associated with nasal polyps.
The biologic treating a patient with all three diagnoses at once may, therefore, be tackling numerous clinical issues simultaneously; this is not an insignificant clinical detail in these patients.
One potential red flag: nasal polyps. They are particularly observed in patients who have aspirin-exacerbated respiratory disease, a triad that consists of asthma, chronic sinusitis and sensitivity to aspirin or NSAIDs.
There are now several approved biologics with nasal polyp indications for clinically integrated practice, and the presence of polyps in challenging individuals with difficult-to-control asthma should be regarded as a major aspect of the clinical scenario.
Age and Approved Indications
Biologic eligibility isn’t limited to adults. Several agents are approved for pediatric patients, though the minimum age varies.
Omalizumab and mepolizumab are approved for asthma down to age 6. Dupilumab carries approval for asthma patients 6 and older as well. Benralizumab is approved starting at age 12. Tezepelumab is currently approved for adults and adolescents 12 and older.
For pediatric patients with severe, uncontrolled asthma and a compatible biomarker profile, biologics are a legitimate part of the conversation and a specialist evaluation is the right place to start it.
What the Evaluation Actually Involves
For patients being evaluated at the Allergy, Asthma & Immunology Institute, the process is methodical. Dr. Laura Ispas has been working in allergy and immunology for over 25 years and is a member of both the American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma & Immunology – organizations whose clinical guidelines directly inform how biologic candidacy is assessed.
An evaluation typically includes a thorough asthma history – how long, how often, what triggers, what has and hasn’t worked – alongside pulmonary function testing to characterize airflow, obstruction, and reversibility. Blood work covers eosinophil counts, total IgE, and other relevant markers. FeNO testing is used where appropriate. Allergy skin testing or specific IgE panels clarify allergic sensitization.
From there, the clinical picture gets assembled: Has standard therapy truly been optimized? Does the biomarker profile fit any approved indication? If more than one biologic could apply, which one addresses the patient’s full picture – including comorbidities – most effectively?
This isn’t a checklist process. It’s a clinical judgment built on everything the patient brings to the table.
A Few Things Worth Clarifying
Biologics are not a cure. They are a long-term, targeted management strategy. Patients who respond well generally continue treatment to maintain results – stopping often leads to a return of symptoms over time.
They are also not a replacement for inhaled corticosteroids in most cases. Standard therapy stays in place; the biologic works on top of it to address the immune drivers that standard medications can’t reach.
The biomarker criteria can seem quite narrow, but actually the approval of tezepelumab really has broadened that eligibility. Patients who previously didn’t fit the eosinophil or IgE thresholds for older agents may now have a viable option, which is worth knowing.
When to Have the Conversation
If your asthma is putting you in the ER, requiring repeated steroid courses, or simply preventing you from living the way you want to – and you’re already on appropriate controller therapy – that gap is worth investigating.
A specialist who understands asthma phenotyping can tell you whether biologic therapy is on the table for you. Not every patient will qualify. But every patient with uncontrolled severe asthma deserves to know whether they do.
Dr. Ispas and the team at the Allergy, Asthma & Immunology Institute in Leesburg, Virginia see patients from across Northern Virginia for exactly this kind of evaluation. If the current plan isn’t holding, there may be more to try – and that conversation starts with a thorough assessment from someone who specializes in it.
Schedule an appointment online at allergy-asthma-immunology.comor call the practice directly at (571) 399-5132!
